FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Other languages Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Real-time Estimate Tradegate Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
18.25 ^EUR	-7.59%		+15.43%	+76.81%

11/06	NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	MT
10/06	Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	11/06
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings	21/05
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	01/04
Newamsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
Newamsterdam Pharma Insider Sold Shares Worth $4,095,234, According to a Recent SEC Filing	28/03
Newamsterdam Pharma Company N.V. Doses First Patient in Phase 3 Tandem Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with Hefh And/Or Ascvd	12/03
NewAmsterdam Pharma Full Year 2023 Net Loss Widens, Revenue Drops	28/02
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
NewAmsterdam Pharma Prices $175.3 Million Public Offering	14/02
NewAmsterdam Pharma Company N.V. Announces Board Changes	08/01
NewAmsterdam Pharma Appoints Ian Somaiya as Chief Financial Officer	23/23/23
NewAmsterdam Pharma Says Alzheimer's Disease Drug Candidate May Improve Cognitive Function	21/23/21
Newamsterdam Pharma Company N.V. Announces Initial Data from Phase 2A Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an Apoe4 Mutation	21/23/21
NewAmsterdam Pharma Company N.V. Appoints William ?BJ" Jones as Chief Commercial Officer	15/23/15
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	07/23/07
NewAmsterdam Pharma Company N.V. Provides Clinical Development Updates	07/23/07
Newamsterdam Pharma Company N.V. Completes Enrollment in Pivotal Phase 3 Broadway Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia And/Or Established Atherosclerotic Cardiovascular Disease	26/23/26
NewAmsterdam Pharma Closes Secondary Offering of Ordinary Shares	10/23/10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Other languages

Filters